BioMarin Pharmaceutical Inc. announced that On December 20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to serve as a member of the Board, effective on December 27, 2023. The Board also appointed each of Ms. Bodem and Mr. Enyedy as a member of the Committee, in each case effective upon their appointment to the Board. The Board has not determined at this time which, if any, other committees Ms. Bodem, Dr. Countouriotis and Mr. Enyedy will be appointed to serve as a member.

In connection with the appointments, the Board determined each of Ms. Bodem, Dr. Countouriotis and Mr. Enyedy to be independent directors within the meaning of the Nasdaq Stock Market listing standards and the rules and regulations of the U.S. Securities and Exchange Commission. Barbara Bodem has extensive Board experience, currently serving on a number of boards including Syneos Health, Enovis Corporation, and BiomEdit. Ms. Bodem is also a board member for the Nature Conservancy of Indiana, a nonprofit working to protect ecologically important lands and waters.

Ms. Bodem recently served as Interim Chief Financial Officer for Dentsply Sirona Inc., the world?s largest manufacturer of professional dental products and technologies. This follows her time as Senior Vice President & Chief Financial Officer, and interim CIO, for Hillrom where she was responsible for both financial and information technology and where she oversaw portfolio transformation and performance acceleration, which led to Hillrom?s successful acquisition by Baxter for $12 billion, inclusive of debt. Prior to this, Ms. Bodem was Senior Vice President of Finance for Mallinckrodt Pharmaceuticals.

At Mallinckrodt, Ms. Bodem was responsible for corporate business development and licensing and reported to the Chief Financial Officer. Before this, she was Vice President of Finance, global commercial operations for Hospira and earlier held several positions of increasing responsibility at Eli Lilly and Company, culminating in Chief Financial Officer, Lilly Oncology. She began her career as a Financial Analyst for Irwin Management Company.

Previously, Ms. Bodem served on the boards of Turning Point Therapeutics and Invacare Corporation. Ms. Bodem earned a M.B. A and a B.S. in Finance both at Indiana University. Athena Countouriotis, M.D., is co founder, President, Chief Executive Officer and Chairperson of Avenzo Therapeutics.

She most recently led Turning Point Therapeutics as President and Chief Executive Officer through its initial public offering (IPO) to its eventual acquisition by Bristol Myers Squibb for $4.1 billion in August 2022. With nearly 20 years of industry experience, she has served as an officer in both public and private companies, led multiple initial public offerings and acquisitions, and guided several development programs to approval in the U.S. and Europe. Dr. Countouriotis previously served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, and as Senior Vice President and Chief Medical Officer of Halozyme Therapeutics.

She also served as Chief Medical Officer of Ambit Biosciences, where she helped lead the company?s IPO and was responsible for the clinical development of Vanflyta until the company?s acquisition by Daiichi Sankyo in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer and Bristol Myers Squibb for oncology therapeutics including Sutent, Mylotarg?, Bosulif and Sprycel. Dr. Countouriotis also serves on the boards of Iovance Biotherapeutics and Passage Bio.

Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial medical training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program. Mark Enyedy has served as the President and Chief Executive Officer of ImmunoGen since 2016.

Mr. Enyedy has nearly three decades of combined general management, business development and legal experience in the biotechnology industry. Mr. Enyedy joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company?s strategy, M&A, and corporate planning functions and providing commercial oversight for the company?s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as Chief Executive Officer and a director of Proteostasis Therapeutics, following 15 years at Genzyme Corporation in diverse roles, most recently as President of the transplant, oncology, and multiple sclerosis divisions.

Before joining Genzyme, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge. Mr. Enyedy also serves on the boards of The American Cancer Society of Eastern New England and the Biotechnology Innovation Organization. He previously served on the boards of Ergomed plc, LogicBio Therapeutics, Akebia Therapeutics, Fate Therapeutics, and Keryx Biopharmaceuticals.

Mr. Enyedy holds a J.D. from Harvard Law School and a B.S. from Northeastern University.